Alkylating agents for Hodgkin's lymphoma tied to secondary leukemia

NEW YORK (Reuters Health) - Reducing exposure to alkylating agents in Hodgkin's lymphoma is key to reducing the risk of therapy-related acute myeloid leukemia or myelodysplastic syndrome (t-AML/MDS), reports a group from Stanford University, California.
Source: Modern Medicine - Category: Journals (General) Source Type: news